rev: July 10, 2003

HOME (index page)

Return (cytokine page)

Cytokines, Growth Factors & Chemokines: 

(Human and others as indicated)

RDI Divison of Fitzgerald Industries Intl  offers a wide line of recombinant growth factors, cytokines and chemokines and antibodies. Since no one antibody works best for all applications (neutralization, blotting, ELISA, etc), we offer many different types of antibodies to help solve this problem. Please inquire for other applications or types of antibodies not listed below.

see also antibodies to VEGFR (FLK-1, FLT etc)

see also new specialty VEGFR1 & VEGFR2 receptors

see also new Elisa kits for  sVEGFR1 (total), VEGF-A

Recombinant Human (sVEGFR-2-FC Chimera) sKDR-Fc chimera

Description: Recombinat Human soluble Endothelial Growth Factor Receptor-2 (sKDRd1-7) was fused with the Fc of human IgG. The soluble receptor protein consists of all 7 extracellular domains, which contain all the information necessary for high affinity ligand binding. The receptor monomers have a mass of approximately 130kDa.

Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.

Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 (sVEGFR-1). No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin.

Source:                     Insect cells

Molecular Weight:   260kDa

Subunit:                    glycosylated dimer

Purity:                       > 90% (SDS-PAGE; HPLC)

Endotoxin level:       < 0.1 ng/ug of sKDR

Stabilizer:                 none

Buffer:                      PBS;pH7.4

Formulation:             lyophilized

Biological Activity: The activity of rh sKDR-FC was determined by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells. The ED50 for for this effect is typically 10.0-30 ng/ml.

Reconstitution: The lyophilized human sKDR-Fc is soluble in water and most aqueous buffers, The lyophilized powder dshould be reconstituted in water or PBS to a concentration of not less than 100ug/ml.

Stability: The material is stable for greater than six months at -20° C to -70° C. After the first thawing it is recommended to aliquote the material, because repeated freeze-thaw cycles will decrease the activity. Store at 4°C not longer than 2 days.

Usage: Human sKDR-Fc is offered for research use. Not for drug use. Not for human use.

Catalogue number:   RDI-S01005  or RDI-SFC-007      Size: 50 µg

Lot number : S10-005.1.2                  

Price: $500.00      $438.00/5+   $406.00/vial 10+

Range: 0.1-10.0 ng/ml   Bulk Quoted on request

-All products are for in vitro research use only-Not for use in or on humans or animals-Not for Diagnostic use. Not responsible for any patent infringements with the use or derivation of these products. Price/specifications/availability subject to change without notice.

HOME (index page)

Return (cytokine page)

RDI Divison of Fitzgerald Industries Intl

34 Junction Square Drive

Concord MA 01742-3049


phone (800) 370-2222

      or (978) 371-6446 or (800) 370-2222

fax     (978) 371-2266

Ordering terms